Are take-home naloxone programmes effective?:Systematic review utilizing application of the Bradford Hill criteria by McDonald, Rebecca & Strang, John
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1111/add.13326
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
McDonald, R., & Strang, J. (2016). Are take-home naloxone programmes effective?: Systematic review utilizing
application of the Bradford Hill criteria. Addiction, 111(7), 1177–1187. 10.1111/add.13326
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
Are take-home naloxone programmes effective?
Systematic review utilizing application of the Bradford
Hill criteria
Rebecca McDonald & John Strang
National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
ABSTRACT
Background and Aims Fatal outcome of opioid overdose, once detected, is preventable through timely administration of
the antidote naloxone. Take-home naloxone provision directly to opioid users for emergency use has been implemented
recently in more than 15 countries worldwide, albeit mainly as pilot schemes andwithout formal evaluation. This system-
atic review assesses the effectiveness of take-home naloxone, with two speciﬁc aims: (1) to study the impact of take-home
naloxone distribution on overdose-related mortality; and (2) to assess the safety of take-home naloxone in terms of adverse
events. Methods PubMed, MEDLINE and PsychINFO were searched for English-language peer-reviewed publications
(randomized or observational trials) using the Boolean search query: (opioid OR opiate) AND overdose AND prevention.
Evidence was evaluated using the nine Bradford Hill criteria for causation, devised to assess a potential causal relationship
between public health interventions and clinical outcomes when only observational data are available.Results A total of
1397 records (1164 after removal of duplicates) were retrieved, with 22 observational studies meeting eligibility criteria.
Due to variability in size and quality of the included studies, meta-analysis was dismissed in favour of narrative synthesis.
From eligible studies, we found take-home naloxone met all nine Bradford Hill criteria. The additional ﬁve World Health
Organization criteria were all either met partially (two) or fully (three). Even with take-home naloxone administration, fa-
tal outcome was reported in one in 123 overdose cases (0.8%; 95% conﬁdence interval = 0.4, 1.2). Conclusions Take-
home naloxone programmes are found to reduce overdose mortality among programme participants and in the commu-
nity and have a low rate of adverse events.
Keywords Bradford Hill, death, heroin, naloxone, opiate, opioid, overdose, prevention.
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INTRODUCTION
Opioid overdose represents a major cause of premature
death [1] and accounts for the majority of deaths among
injection drug users (IDUs) world-wide [2]. Opioid overdose
deaths are preventable through timely administration of
naloxone, a potent mu-opiate antagonist that rapidly re-
verses opiate-induced respiratory depression.
In 2014, the World Health Organization (WHO)
launched guidelines on the community management of
opioid overdose [3], recommending that ‘people likely to
witness an opioid overdose should have access to naloxone
and be instructed in its administration’ (p. x).
The community-based provision of naloxone rescue
kits to opioid users (‘take-home naloxone’, THN) was
ﬁrst proposed in the 1990s [4]. THN programmes typ-
ically involve training opioid users and/or their family
members or peers in overdose risk awareness, over-
dose emergency management and naloxone adminis-
tration [5]. During the past 15 years, THN
programmes have been implemented in Europe, North
America, Asia and Australia [1]. However, the vast
majority of evaluations have been pilot schemes with
uncontrolled study designs.
The evaluation of THN programmes is challenging:
randomized controlled trials (RCTs) are often considered
the gold standard of scientiﬁc study of clinical impact, but
conducting such trials in this context would often be un-
ethical and fraught with methodological difﬁculties, given
the infrequency and unpredictability of overdose.
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Critics of THN programmes argue that the existing ob-
servational data are not strong enough to infer causation
from naloxone provision to the reduction of overdose
deaths [6,7]. A counter-argument may be that similar res-
ervations initially blocked other harm reduction strategies,
including needle exchange programmes and opioid substi-
tution therapy [8] that are nowevidence-based practice [9]
(andwould still be absent if the precautionary principle had
been strictly applied).
A clearer understanding of the potential beneﬁts and
risks of THN provision is essential. If concerns are valid
they need to be identiﬁed and considered in context, but
mere assertions of hypothetical disadvantages must not
prohibit access to a life-saving medication. A previous sys-
tematic review [10] found that participation in THN
programmes led to improved overdose-related knowledge
as well as appropriate use and administration of naloxone,
but the impact on overdose mortality was not assessed.
Our goal in this review is to assess the effectiveness of
THN programmes by following a well-recognized process
(i.e. Bradford Hill criteria) rigorously to evaluate the data
within eligible studies, addressing the following two aims:
(1) to describe the impact of THN provision on overdose-
relatedmortality in opioid users; and (2) to assess the safety
of THN provision by quantifying adverse events associated
with naloxone administration.
METHODS
A systematic literature search was performed following
PRISMA (Preferred Reporting Items for Systematic Re-
views andMeta-Analyses) guidance (see Fig. 1 for PRISMA
ﬂow diagram and Supporting information, Appendix S1 for
search protocol and excluded studies).
Identiﬁcation of eligible studies
Electronic databases were searched to identify relevant
peer-reviewed papers published between January 1946
and June (third week) 2015. Replicating the search strat-
egy reported by Clark et al. [10], the following Boolean
search query was used: (opioid OR opiate) AND overdose
AND prevention.
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ﬂow diagram of study selection process
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Electronic database searching generated 1397 records:
150 onMedline, 772 on PsycInfo (both via OVID) and 475
on PubMed. Five studies [11–15] were added after a man-
ual search of the reference lists of recent literature reviews
[10,16,17].
Original quantitative (or mixed-method) studies of
randomized or observational trials of THN programmes
that trained opioid users in overdose prevention AND re-
ported on overdose outcomes were included into the
study. Several exclusion criteria were applied: reporting
on buprenorphine/naloxone; case reports; not reporting
primary research data; not reporting on heroin/opioid
users, naloxone or overdose.
Under supervision of the senior investigator, the ﬁrst
author extracted data using the STROBE (Strengthening
the Reporting of Observational Studies in Epidemiology)
checklist [18], assessed study eligibility and conducted
quality appraisal using an eight-item scale by Jinks et al.
[19], which had been applied previously by Clark et al.
[10] (see Table 4).
All 22 studies that met the inclusion criteria were en-
tered into the analysis. Among these, one was an
interrupted time–series analysis that provided quasi-
experimental data. Sixteen were pre–post studies (nine
with systematic follow-up), three were case series and
two were cross-sectional. None of the studies involved ran-
domization to the intervention (i.e. THN distribution), al-
though two studies were controlled [12,20]. Of the 22
included studies, 15 were carried out in the United States,
two in Canada, four in the United Kingdom and one in the
United Kingdom and Germany (multi-site). Sample sizes
varied from aminimum of 24 to a maximum of 2912 (me-
dian: n = 203).
Analysis
There was large variability in the size and quality of the
THN intervention studies identiﬁed: for example, many
were merely descriptive reports which, while valuable
communications to other practitioners, were neverthe-
less lacking study design or analytical rigour. Moreover,
while nine studies involved systematic follow-up, they
were not considered necessarily representative of the ma-
jority of included studies due to small sample sizes. As a
consequence, narrative synthesis was chosen as the
more appropriate method of analysis in lieu of meta-
analysis.
In this context, the evidence was evaluated using the
Bradford Hill criteria [21], a set of nine criteria (see Table 1)
devised in 1965 by British epidemiologist and statistician
Sir Austin Bradford Hill to assess causality when only cor-
relational data are available: (1) strength of association,
(2) consistency, (3) speciﬁcity, (4) temporality, (5) dose–
response relationship, (6) plausibility, (7) coherence, (8)
experimental evidence and (9) analogy. The Bradford Hill
criteria are considered a standard tool to assess the impact
of broad-based public health interventions where it is not
ethically feasible or operationally impractical to conduct
RCTs.
The Bradford Hill criteria have been applied valuably in
a WHO ‘Evidence for Action’ report [22] on the effective-
ness of needle-exchange interventions in reducing HIV
among IDUs. TheWHO report also considered evidence ac-
cording to ﬁve additional criteria relating to feasibility and
implementation (see Table 2), which we include as supple-
mentary analysis: (10) cost-effectiveness; (11) absence of
negative consequences; (12) feasibility of implementation,
expansion and coverage; (13) unanticipated beneﬁts; and
(14) special populations.
Where summary outcome measures (e.g. number of
naloxone administrations, overdose reversals, adverse
events) were calculated across studies, we sought to
avoid (partial) duplication of samples by including only
the study with the largest participant sample per project
[20,23] for THN projects that had produced more than
one published study (i.e. Boston/Massachusetts, Los
Angeles, New York, San Francisco). Vice versa, if the
time-periods covered by multiple studies from the same
project could be distinguished clearly and did not over-
lap, all project evaluations entered analysis [24–27].
All summary statistics are pooled, unweighted estimates
from the referenced studies. The number of overdose re-
versals is used as proxy for the impact of THN provision
on opioid overdose mortality (aim 1), as a ratio of one
fatal overdose in every 20 overdose events has been de-
scribed in the literature [28], and it is impossible to
ascertain for each overdose event whether, in the
absence of intervention, the outcome would have been
fatal or whether respiratory function would have
recovered.
RESULTS
We now present the ﬁndings from application of the nine
original Bradford Hill criteria [21], followed by consider-
ation of the extra ﬁve criteria added in the WHO report
[22,29].
Consideration according to the original Bradford Hill
criteria
Strength of association
In 21 of the 22 studies, pre-provision of naloxone was
followed by use of the naloxone to reverse opioid overdose.
After exclusion of four studies that possibly contained
duplicate samples [30–33], a total of 2336 THN administra-
tions were found across 17 studies (see Table 3). Due the
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binary outcome (survival/death), the number of successful
overdose reversals can be estimated by deducting the num-
ber of deaths from the number of THN administrations. By
deducting the 20 conﬁrmed deaths (1 + 1 + 2 + 6 + 10)
where overdose victims did not recover following naloxone
administration [12,24,25,34,35], we obtain an upper esti-
mate of 2316 successful overdose reversals.1 If the four
deaths where it was unclear if naloxone had been adminis-
tered [23] and 63 cases (8 + 36 + 14 + 5) of naloxone ad-
ministration with ‘unknown outcome’ [23,24,27,34] are
12316 overdose (OD) reversals = 2336 THN administrations minus 20 deaths (see Table 3).
Table 3 Included studies: naloxone kits distributed and used, overdose reversals and adverse events.
Study n
THN kits
distributed
THN kits
used (%) Deaths
OD reversal
after THN e
Unknown
outcomes Adverse reactions
Bennett 2011 426 426 249 (58%) 2 ≥ 96% 8 NR
Bennet 2012 525 NR 28 (NR) 1 96% NR
Dettmer 2001f 101 101 5 (5%) 0 100% Withdrawal (NR)
Dettmer 2001f 124 124 29 (23%) 0 100% Withdrawal (10)
Doe-Simkins 2009d 385 385 74 (19%) 0 100% Withdrawal (2)
Dwyer 2015d 415 56 6 (11%) 0 100% NR
Enteen 2010 1942 2962 399 (13%) 6 ≥ 89% 36 Vomiting (50),
agitation (36),
seizures (3)
Galea 2006 25 25 10 (40%) 1a 100% 1a None
Lankenau 2013d 30 30 15 (50%) 0 ≥ 97% 1 NR
Leece 2013 209 209 17 (8%) 0 100% None
Lopez-Gaston 2009 70 70 0 (0%) 1a NA NA
Markham Piper 2008 122 122 82 (67%) 0 ≥ 83% 14 NR
Maxwell 2006 1120 3500 319 (9%) 1c 99% Seizures (1),
vomiting (1)
McAuley 2010 41 19 2 (11%) 1a 100% NR
Rowe 2015 2500 2500 702 (28%) 10 99% NR
Seal 2005 24 24 15 (63%) 0 100% NR
Strang 2008 239 239 1 (5%) 1a 100% Withdrawal
Tobin 2009 250 250 22 (9%) 0 100% NR
Tzemis 2014 692 836 85 (10%) 0 100% Withdrawal (55),
agitation (9)
Wagner 2009 66 66 28 (42%) 4b NR 5 Agitation (5),
vomiting (1)
Walley 2013 [20] 2912 2912 327 (11%) 0 100% NR
Walley 2013 [33]d 1553 1553 92 (6%) 0 100% NR
Yokell 2011 120 120 5 (4%) 0 100% NR
aNaloxone not administered; bunclear if naloxone administered; cnon-opioids present; NA: not applicable; NR: not reported; OD = overdose; THN: take-home
naloxone; dnot included in summary measures to avoid (partial) duplication of samples; ewhere applicable, unknown outcomes were counted towards
unsuccessful THN administrations (as indicated by the ≥ symbol); fMulti-site study with two samples: Jersey (n=101) and Berlin (n=124).
Table 2 Additional feasibility and implementation criteria and application to take-home naloxone.
Criterion Take-home naloxone (THN)
Cost-effectiveness Is THN for lay overdose reversal cost-effective compared to treatment as
usual (no intervention)?
Absence of negative consequences Does the distribution of THN to users bear the risk of adverse events?
Feasibility of implementation, expansion,
and coverage
Is it feasible to introduce THN distribution in diverse settings, including
resource-poor settings, and scale up implementation?
Unanticipated beneﬁts Does the distribution of THN to users lead to unanticipated beneﬁts?
Special populations How successful are THN programmes in reaching special populations that
have been identiﬁed as particularly ‘at-risk’ opioid users?
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also counted towards fatalities following naloxone adminis-
tration, a conservative, lower estimate of 2249 successful
overdose reversals2 emerges. In the only study where THN
provision did not lead to overdose reversals [11], nine of
46 programme participants witnessed a total of 16 over-
doses at 6-month follow-up, but none administered nalox-
one to the overdose victims. The main reason for non-
administration was that participants did not have their nal-
oxone supply available.
In summary, there is a strong association between THN
programmes and overdose survival, as evidenced by at
least 2249 successful overdose reversals [96.3%; 95% con-
ﬁdence interval (CI) = 95.5, 97.1] among 2336 THN
administrations.
Temporality
In 21 of the 22 studies, training in overdose prevention
and THN provision preceded overdose reversals. Two of
these studies provide clear evidence in support of the
temporality criterion. Supportive evidence comes from
descriptive accounts of early THN distribution in Chicago
and surrounding Cooks County [35]: after a 135% in-
crease in local overdose deaths from 1996 to 2000, the
introduction of THN in 2001 led to reduction in fatal
overdoses by 20% in 2001, 8% in 2002 and 6% in
2003 (compared to past-year rate). While these data
are indicative of a temporal sequence between THN in-
troduction and reduced overdose mortality, no deﬁnite
conclusion can be drawn, as the lack of control group
means that other causes may have contributed to de-
creasing overdose mortality rates.
Stronger evidence comes from Walley et al. [20] who
conducted an evaluation of a state-funded THN pro-
gramme in Massachusetts. Between 2006 and 2009, the
Massachusetts Department of Public Health used a phased
roll-out to introduce THN in 19 communities, enrolling
2912 individuals in total. To evaluate the impact of THN,
Walley et al. used an interrupted time–series analysis,
where each community served as its own geographic con-
trol and communities without concurrent THN availability
served as time control. For all 19 participating communi-
ties, overdose mortality rates in the time-periods before
and after THN implementation were compared. Overdose
mortality rates were reduced signiﬁcantly in communities
where THN was implemented, compared to pre-
implementation rates and to communities without THN.
Consistency
Overdose reversals by means of THN have been docu-
mented in the selected studies by independent investigators
22249 overdose (OD) reversals = 2336 THN administrations minus 20 deaths minus four unclear cases minus 63 cases with unknown outcome.
Table 4 Included studies: follow-up rate, study design and quality rating.
Study Location n FU FU % FU type Design Score
Bennett 2011 Pittsburg 426 89 21% Non-systematic Pre–post 5
Bennet 2012 Wales 525 28 5% Systematic Pre–post 6
Dettmer 2001a Jersey 101 NR NR Non-systematic Case series 4
Dettmer 2001a Berlin 124 40 32% Non-systematic Case series 4
Doe-Simkins 2009 Boston 385 278 72% Non-systematic Pre–post 5
Dwyer 2015 Boston 415 51 12% Systematic Pre–post 6
Enteen 2010 San Francisco 1942 310 16% Non-systematic Pre–post 6
Galea 2006 New York 25 22 88% Systematic Pre–post 7
Lankenau 2013 Los Angeles 30 NA NA NA Cross-sectional 6
Leece 2013 Toronto 209 NR NR Non-systematic Case series 5
Lopez-Gaston 2009 Birmingham & London 70 46 65% systematic Pre–post 7
Markham Piper 2008 New York 122 NR NR Non-systematic Pre–post 6
Maxwell 2006 Chicago 1120 NR NR Non-systematic Case series 4
McAuley 2010 Lanarkshire 41 17 89% Systematic Pre–post 7
Rowe 2015 San Francisco 2500 613 25% Non-systematic Pre–post 7
Seal 2005 San Francisco 24 24 100% Systematic Pre–post 5
Strang 2008 England 239 186 78% Systematic Pre–post 7
Tobin 2009 Baltimore 250 85 34% Systematic Pre–post 6
Tzemis 2014 British Columbia 692 NA NA NA Cross-sectional 6
Wagner 2009 Los Angeles 66 47 71% Systematic Pre–post 7
Walley 2013 [20] Massachusetts 2912 212 7% Non-systematic ITS 7
Walley 2013 [33] Massachusetts 1553 286 18% Non-systematic Pre–post 6
Yokell 2011 Rhode Island 120 10 8% Non-systematic Pre–post 5
FU: number of follow-up participants; FU%: FU participants as percentage of study sample; ITS: interrupted time–series analysis; NA: not applicable; NR: not
reported; score: summary quality score based on eight-point scale by Jinks et al. [19], modiﬁed from Clark et al. [10] aMulti-site study with two samples (Jersey,
Berlin).
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under different circumstances in at least 15 different cities,
states and countries: in Canada (Toronto and British
Columbia), the United States (Baltimore, Boston/
Massachusetts, Chicago, Los Angeles, San Francisco, New
York, Pittsburgh, Rhode Island), the United Kingdom
(England, Jersey, Scotland, Wales) and Germany (Berlin).
Overdose reversals by THN have also been documented re-
peatedly in New York [26,27] and San Francisco
[14,24,25]. In conclusion, there is substantial support for
the consistency criterion.
Biological plausibility
This criterion addresses the therapeutic effect of naloxone.
Naloxone is a pure opioid antagonist that binds to the μ-
opioid receptor and blocks competing agonists, such as
heroin [36]. All but one study [11] reported on THNadmin-
istration in cases of suspected opioid overdoses, and the
pharmacological effects of naloxone led to at least 2249
overdose reversals. In conclusion, there is strong empirical
support to the biological plausibility criterion.
Coherence
Declining overdose rates in the absence of THN have been
reported in the literature. The Australian heroin drought
constitutes a prominent example, where between 2001
and 2002 overdose-related mortality rates dropped in con-
junction with a shortage in illicit heroin imports. THN
could not have accounted for the decline in mortality, as
it was introduced in Australia only in 2011 [37,38]. How-
ever, the Australian example does not conﬂict with the pre-
sumed effect of THN on reduced overdose mortality. The
cause-and-effect interpretation of our data is consistent
with current understanding of the mechanisms of opioid
overdose, and the 21 studies which reported overdose re-
versals provide strong support for the coherence criterion.
Speciﬁcity
The speciﬁcity criterion relates to efﬁcacy of the interven-
tion (the same as biological plausibility), rather than
population-wide effectiveness. THN exclusively reverses
opioid-induced overdoses, as illustrated by the following
two cases: in the Dettmer et al. study [39], naloxone
had zero effect when administered to a person suffering
from cocaine intoxication. The Chicago Recovery Alli-
ance reported one fatality after naloxone administration
[35] where naloxone failed to revive an overdose victim
with non-opioids in their system. The mooted beneﬁt
from naloxone is speciﬁc to opioid overdose. In practice,
THN may be primarily beneﬁcial for the reversal of over-
doses from heroin and other short-acting opioids. (All 22
studies reported primarily on heroin overdoses, and one
study speciﬁed that the long-acting opioid methadone
was involved in less than 5% of overdose reversals
[33].) Overall, the evidence constitutes strong support
for this criterion.
Dose–response relationship
Researchers estimate that THN distribution can only
achieve maximum impact on overdose reduction if a cer-
tain volume of THN kits is available in the community.
Among the 22 studies, only Walley et al. [20] assessed
the impact of varying degrees of THN availability on over-
dose mortality by splitting the 19 participating communi-
ties into three groups based on volume of THN
distribution: zero implementation, low implementation
(1–100 programme enrolments per 100 000 inhabitants)
and high implementation (>100 enrolments). Both low
and high implementers had signiﬁcantly reduced overdose
mortality rates compared to communities without imple-
mentation, and there was a signiﬁcant implementation
dose-relationship with overdose death rates, with greatest
effect with greatest implementation.
To summarize, there is only this limited empirical evi-
dence for a dose-related impact of THN availability, and
hence this criterion is only partially fulﬁlled.
Experimental evidence
While none of the 22 studies deliver experimental evi-
dence, the interrupted time–series analysis by Walley
et al. [20] provides quasi-experimental evidence in sup-
port of causation. Importantly, even communities with
low-level THN implementation of THN (1–100 partici-
pants, see above) saw a reduction in overdose mortality,
compared to communities without THN distribution.
Interrupted time–series analysis is considered to be the
strongest quasi-experimental research design [40]. The
results of the study by Walley et al. [20] thus provide
preliminary support for the experimental evidence
criterion.
Analogy
THN is analogous to naloxone treatment for the same clin-
ical indication in emergency medical care, and also to the
prescription of other emergency medications (typically an-
tidotes for overdose or poisoning) for peer administration:
THN has been compared to the provision of adrenaline in-
jection kits (e.g. EpiPen) to individuals with severe allergic
reactions for family members to administer in the event
of anaphylactic shock [15] or the provision of glucagon
for insulin overdose [35]. Similarly, THN has been likened
to pre-placement of deﬁbrillators and cardiopulmonary re-
suscitation (CPR) training for lay people likely to witness
cardiac arrest [41]. For all these emergency interventions,
timely delivery is crucial.We conclude that the analogy cri-
terion is fulﬁlled.
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Consideration according to additional feasibility and
implementation criteria
Cost-effectiveness
Separate modelling data from both the United States and
Russia conclude that THN is cost-effective even under con-
servative circumstances, i.e. when the cost of naloxone in-
creases and the rate of observed overdoses decreases
[42,43]. Bearing in mind the potential limitation that both
studies were conducted by the same authors, there is con-
sistent evidence for the cost-effectiveness of THN.
Absence of negative consequences
In ﬁve of the 17 studies that did not contain duplicate sam-
ples, 20 overdose victims did not survive naloxone admin-
istration [12,24,25,34,35]. In addition, Wagner et al.
[23] reported four deaths where it was unclear if naloxone
had been administered. Based on these observations, the
following fatality rates emerge: 20 conﬁrmed deaths per
2336 naloxone administrations (0.9%; 95% CI = 0.5,
1.2) or 24 deaths per 2336 naloxone administrations
(1.0%; 95% CI = 0.6, 1.4) if we include the four fatalities
where it was unclear if naloxone had been administered.
If we limit the study selection to the nine papers with sys-
tematic follow-up, a similar ratio of one conﬁrmed death
per 123 naloxone administrations (0.8%; 95% CI = 0.4,
1.2) was observed.
In six [15,23,24,35,39,44] of the 17 studies, several
adverse reactions were reported in conjunction with a total
of 2336 naloxone administrations: at least 65 instances of
withdrawal symptoms (2.8%), 52 cases of vomiting
(2.2%), 50 cases of agitation (2.1%) and four seizures
(0.1%).
In conclusion, THN programmes have a low rate of ad-
verse events. Where adverse reactions occurred, these
were most frequently symptoms of opioid withdrawal (in-
cluding nausea/vomiting, agitation).
Feasibility of implementation, expansion and coverage
The 22 studies document THN implementation in a variety
of settings across 16 geographical locations, and naloxone
usage rates between 5 and 63% are reported. San
Francisco is an example of rapid expansion, as the volume
of THN kits distributed increased from 24 in 2001 to 2962
kits during the 6-year period between 2003 and 2009 (i.e.
approximately 494 kits/year) [24], and to 2500 kits from
2010 to 2013 (i.e. approximately 833 kits/year) [25]. Out-
side the 22 studies included in this review, implementation
in resource-poor settings has been achieved in Kyrgyzstan
and Tajikistan, with reported naloxone usage rates of 47
and 78%, respectively [45]. These studies suggest that
THN schemes are capable of implementation across a wide
range of settings and cultures.
Unanticipated beneﬁts
Four of the 22 studies reported unanticipated beneﬁts. In
THN programmes in California, 25% of participants in
San Francisco entered treatment within 6-month follow-
up [14] and 53% of participants in Los Angeles reported
decreased drug use at 3-month follow-up [23]. Similarly,
Maxwell et al. reported anecdotal evidence of increased
willingness among THN recipients to be tested for HIV
and hepatitis C virus (HCV) [35]. Strang et al. [15] found
a secondary training effect: within a 3-month follow-up pe-
riod, 28% of THN recipients had trained a family member
or peer.
Special populations
THN provision has been implemented successfully in
programmes targeting special populations with high risk
of overdose: detox patients [11,33], homeless users [23–
25,27,46], methadone patients [33] and prison inmates
[12]. The Massachusetts THN programme [20] also en-
rolled attendees of HIV education centers, and a Los
Angeles-based programme recruited more than 50%
HCV-positive patients. Both represent particularly vulnera-
ble groups due to their comorbid health issues and risk of
blood-borne virus transmission by needle-sharing. From
the perspective of implementation, THN schemes can be
delivered to populations in special need.
Summary of ﬁndings
Empirical evidence from the 22 studies reporting on THN
interventions for opioid users meets all nine Bradford Hill
original criteria. Among these, Sir Austin Bradford Hill
considered the experimental evidence criterion to deliver
the strongest support for causation [21], but only quasi-
experimental evidence from one study [20] is available
here. The robustness of empirical support ranges from
one study per criterion (dose–response, experimental evi-
dence) to 21 studies per criterion (strength of association,
coherence) (see Supporting information, Appendix S1).
With regard to the ﬁve additional criteria assessing feasibil-
ity and implementation, THN fulﬁls fully or partially all ﬁve
criteria. It is found to be cost-effective, and existing projects
were able to access and train high-risk populations that led
to 2336 layperson naloxone administrations (aim 1) with
a low rate of adverse effects (aim 2).
DISCUSSION
Application of the Bradford Hill criteria to the current evi-
dence base on THN supports the causation hypothesis.
While the evidence is sometimes based on only one or
two studies, we nevertheless conclude that this constitutes
support for all nine criteria. THN provision reduced fatal
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outcome of overdose among programme participants
themselves, among fellow opioid users and in the wider
community, as evidenced by public vital statistics records
[14,20]. Alternative explanations for this observation are
unlikely: in control communities that did not implement
THN, opioid overdose mortality was signiﬁcantly higher
[20]. The risk associated with THN programmes is rela-
tively low, especially when the life-threatening nature of
the emergency situation is borne in mind: in studies with
systematic follow-up, one death was reported among 123
overdose victims who were administered THN. Moreover,
there is no empirical evidence to support the concern that
THN programmes might encourage heroin use. Two stud-
ies reported decreased drug use among THN programme
participants at follow-up [14,23], whereas a more recent
study found no overall change in the frequency of heroin
use across THN recipients [47].
This is the ﬁrst published application of the BradfordHill
criteria to assess the international evidence base on THN.
Our ﬁndings extend and substantiate the 2014 WHO
Guidelines as well as the results of the previous systematic
reviews by Clark et al. [10] and the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) [17].
Clark et al. (2014) cautiously concluded: ‘participation [in
THN programs] is associated with overdose reversals’ (p.
162), but avoided statements on the effectiveness of THN,
whereas the EMCDDA stated: ‘there is evidence that
educational and training interventions with provision of
take-home naloxone decrease overdose-related mortality’
(p. 11).
There are potential limitations to this analysis, which
need to be borne in mind. Selection bias may have affected
the internal validity of the data included. Among 19 stud-
ies with pre–post and case series designs, 10 relied on un-
systematic follow-up to capture overdose events and
naloxone usage, relying upon spontaneous follow-up, with
THN programme participants asked typically to report
back on naloxone usage when collecting a naloxone reﬁll.
This raises scientiﬁc analytical doubt about data quality
and interpretations: ﬁrst, across these 10 studies, fewer
than a quarter (22.9%; i.e. 1973 of 8602) of THN recipi-
ents returned for reﬁlls after THN use, and information
on the majority of participants was consequently lost. Sec-
ondly, it is possible that users with positive naloxone expe-
riences (e.g. successful overdose reversals) may be more
likely to return for a reﬁll of their THN kit and complete a
follow-up survey, whereas those with negative naloxone
experiences may not be captured in the follow-up. The lack
of systematic follow-up in themajority of studies is reﬂected
in the wide range of follow-up rates attained across all
studies (min. 5%, max. 100%). High levels of dropout can
reduce the external validity and generalizability of results.
A further source of potential bias lies in the fact that, for
21 of the 22 studies, there was an exclusive reliance on
self-report data for overdose outcomes. Only the
interrupted time–series analysis by Walley et al. [20] in-
cluded a public database of vital statistics to calculate over-
dose fatality rates. A further limitation concerns the fact
that the experimental evidence and dose–response criteria
hinge on data from the Walley et al. [20] study. More well-
conducted studies are needed to conﬁrm these results and
assess their applicability to other regions internationally,
in particular low- and middle-income countries. Moreover,
the ﬁndings from the studies do not inform which distribu-
tion model of overdose education and THN distribution is
preferable. Future studies could evaluate the impact of pro-
gramme components formally by providing THN to all sub-
jects and randomizing subjects into different training
conditions (e.g. ‘overdose education’ versus ‘overdose edu-
cation + CPR training’).
Despite these methodological limitations, positive re-
ports of overdose reversals following THN distribution were
reported across 21 studies, regardless of type of follow-up
(systematic versus unsystematic) or data source (self-re-
port versus objective data), suggesting that the ﬁnding is
indeed robust and not an artefact of methodological ﬂaws.
To control for potential publication bias, we additionally
searched the grey literature for documents reporting on
THN initiatives that are not published in the peer-reviewed
journal domain. While this search was probably not ex-
haustive, the data reported in the grey literature are
broadly consistent with the results of the studies included
in our systematic review. For instance, in the Scottish Na-
tional Naloxone Programme, in 2012 and 2013 the per-
centage of opioid-related deaths occurring within
4 weeks of prison release (5.5 and 4.7%) was almost half
that of the pooled 2006–10 baseline indicator (9.8%), sug-
gesting that distribution of naloxone kits on releasemay re-
duce the risk of fatal overdose among (former) prisoners
with history of opioid use [48].
With regard to clinical implications, it needs to be em-
phasized that the vast majority of studies included in this
review reported on heroin overdoses. Consequently, the
generalizability of our ﬁndings to overdoses from long-
acting opioids is unclear. Even when methadone patients
were recruited speciﬁcally into a THN programme [33],
more than 90% of witnessed (and reversed) overdoses were
heroin-induced. The results of this review on the effective-
ness of THN are thus limited to impact on heroin overdoses,
and the effectiveness of the intervention for overdoses from
long-acting opioids (e.g. methadone or many prescription
opioids) needs to be explored in future research.
To conclude, application of the Bradford Hill criteria to
the current evidence base from non-randomized studies
ﬁnds that THN programmes have led to improved survival
rates among programme participants and reduced heroin
overdose mortality rates in the community (aim 1) and
are accompanied by only a low rate of adverse events
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(aim 2). In the absence of RCTs, we conclude that THN dis-
tribution to at-risk users should be introduced as standard
of care for the community-based prevention of heroin over-
dose deaths.
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